Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.060
+0.010 (0.49%)
At close: Aug 18, 2026, 4:00 PM EDT
2.097
+0.037 (1.82%)
After-hours: Aug 18, 2026, 6:00 PM EDT
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
118.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Seer, Inc. | 14.22M |
| Coya Therapeutics | 8.02M |
| Inovio Pharmaceuticals | 65.34K |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
BDTX News
- 12 days ago - Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2 - TheFly
- 12 days ago - Black Diamond Therapeutics setup ‘attractive,’ says Jefferies - TheFly
- 13 days ago - Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c) - TheFly
- 13 days ago - Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 13 days ago - Black Diamond Therapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - Black Diamond Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Black Diamond Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts